Natco Pharma receives exchange approvals in principle for proposed rights issue
As filed · Natco Pharma Limited has informed the Exchange regarding 'Intimation regarding receipt of In-Principle Approval for the Rights Issue '.
What happened
FactNatco Pharma said it received in-principle approval from the NSE and BSE on September 21, 2026, for a rights issue of fully paid-up equity shares. The company said copies of the approval letters are available on its website.
Why it matters
CapitSignal interpretationExisting holders can maintain their stake only by putting in more money; those who do not subscribe are diluted.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
RevisedI think we will end the year with another extra Rs 250 to 300 crores of extra PAT we were expecting.
So, we expect the cash will be around maybe Rs 2,700 crores, 2,800 crores is what we are expecting a cash will settle around.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Rights ratio and issue price
- Record date and subscription window
- Promoter intention to subscribe
- I think we will end the year with another extra Rs 250 to 300 crores of extra PAT we were expecting. (management committed by FY25)
- So, we expect our run rate to be around Rs 750 to 800 crores of revenue, and a PAT should be around Rs 135 to (management committed by H1 FY25)
Evidence
- Natco Pharma Limited has informed the Exchange regarding 'Intimation regarding receipt of In-Principle Approval for the Rights Issue '.(opens the original filing in a new tab)
- Earlier statement · Q2 FY25
- Latest statement · Q2 FY25
- Earlier statement · Q2 FY25
How CapitSignal classified this
- Reasoning:
- The approvals represent a procedural step toward the proposed rights issue, but the filing does not disclose the issue size, price, ratio, timetable, or intended use of proceeds.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%